Breakthrough Math: Alexion Gains $400 Million on Asfotase Breakthrough Designation
This article was originally published in RPM Report
Executive Summary
There’s a lively debate underway as to what FDA’s new breakthrough designation means for a sponsor and for the likelihood of a product’s regulatory and commercial success. Alexion’s post-Memorial Day bump dramatizes the positive impact on Wall Street.